Navigation Links
Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016

Huge Opportunity Exists for Development of More Effective Therapies That Can Improve Survival, According to a New Report from Decision Resources

WALTHAM, Mass., Sept. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the emergence of cancer vaccines, including drugs from Pharmexa and Cell Genesys, will be the key factor driving the pancreatic cancer drug market to more than double by 2016.

The new Pharmacor report entitled Pancreatic Cancer finds that Pharmexa's GV1001 and Cell Genesys's GVAX will drive the market from $560 million in 2006 to $1.2 billion in 2016 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The report also finds that, owing to generic erosion, sales of cytotoxic therapies used in pancreatic cancer -- Eli Lilly's Gemzar, Sanofi-Aventis's Eloxatin/Yakult Honsha's Elplat, Pfizer/Yakult's Campto/Camptosar, Daiichi-Sankyo's Topotecin, and Sanofi-Aventis's Taxotere -- will decline significantly during the next decade.

Although it accounts for only about two percent of all cancers, pancreatic cancer -- one of the most difficult cancers to treat -- is the fourth leading cause of cancer deaths in the United States. As a result, the pancreatic cancer market carries extensive unmet medical need, creating a huge opportunity for the development of more effective therapies that can improve survival.

"In combination with Gemzar, the most promising emerging therapies have failed to improve survival in large-scale, Phase III studies," said Mary Argent-Katwala, Ph.D., director at Decision Resources. "Experts argue that the development model for pancreatic therapies needs to be reviewed, that more effort should be directed at identifying responder subsets at an earlier stage of the disease, and that randomized Phase II studies to identify the most promising drug candidates should be more widely implemented."

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Emergence of Internet video is changing the regulatory landscape
2. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer
3. Cancer siRNA Oligo Set Version 1.0
4. Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform
5. Detection of Mutant K-ras in a Kindred With Hereditary Pancreatic Cancer by DGGE
6. Detection of p53 Gene in Breast Cancer by Denaturing Gradient Gel Electrophoresis and the DCode System
7. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
8. Genome Wide Profiling of Paired Cancerous and Normal Breast Tissues and Rapid Interpretation of Gene Expression Data
9. NeoClone gets $750K for ovarian cancer detection
10. Quintessence Biosciences advances cancer drug
11. Medical College receives $1.4M cancer grant
Post Your Comments:
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
(Date:10/9/2017)... ... 2017 , ... At its national board meeting in North Carolina, ARCS® ... Departments of Physics and Astronomy, has been selected for membership in ARCS Alumni ... the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion ...
Breaking Biology Technology:
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):